Lv31
256 积分 2023-11-21 加入
Appraising the Tail of the Survival Curve in the Era of PD-1/PD-L1 Checkpoint Blockade
1小时前
待确认
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
13天前
已完结
Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study
27天前
已完结
Binding of inhibitory checkpoints to CD18 in cis hinders anti-cancer immune responses
28天前
已完结
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer
1个月前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
2个月前
已完结
Haplotypes of FcγRIIa and FcγRIIIb Polymorphic Variants Influence IgG-Mediated Responses in Neutrophils
3个月前
已完结
Kindlin3-Dependent CD11b/CD18-Integrin Activation Is Required for Potentiation of Neutrophil Cytotoxicity by CD47-SIRPα Checkpoint Disruption
3个月前
已完结
Ivonescimab in non-small cell lung cancer: harmonizing immunotherapy and anti-angiogenesis
3个月前
已完结
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study
4个月前
已完结
皖公网安备34019202002308
